PDCD1 and urothelial carcinoma: Although there were no positive results in the renal cell carcinoma and advanced uroepithelial carcinoma cohorts, we found significantly low expression of ARRB1 in the responder group in the metastatic melanoma anti-PD1 therapy cohort.